Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

B&L Retisert Drug Delivery Implant FDA Filing Delayed By One Year

This article was originally published in The Gray Sheet

Executive Summary

Bausch & Lomb will wait for results from its second pivotal trial for the Retisert drug-delivery implant for treating posterior uveitis before submitting a new drug application to FDA, which is expected in mid-2004

You may also be interested in...



B&L Expanded Drug-Delivery Products Seen As Springboard To Future Growth

Bausch & Lomb continues to transform itself into a drug-delivery eyecare company from a traditional contact lens firm, with implants and molecular compounds in various stages of development

Connected Strategies Are Vital For Medtechs In The Consumer-Led 2020s

Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.

UsernamePublicRestriction

Register

MT017955

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel